H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) dropped 49.5% on Monday . The company traded as low as $2.02 and last traded at $2.02. Approximately 400 shares were traded during trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Performance
The company has a fifty day simple moving average of $2.02 and a two-hundred day simple moving average of $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Stories
- Five stocks we like better than H-CYTE
- Trading Halts Explained
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- How to find penny stocks to invest and trade
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
